Compare · XBIT vs XNCR
XBIT vs XNCR
Side-by-side comparison of XBiotech Inc. (XBIT) and Xencor Inc. (XNCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both XBIT and XNCR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- XNCR is the larger of the two at $2.58B, about 48.9x XBIT ($52.7M).
- XNCR has been more active in the news (12 items in the past 4 weeks vs 7 for XBIT).
- XNCR has more recent analyst coverage (23 ratings vs 0 for XBIT).
- Company
- XBiotech Inc.
- Xencor Inc.
- Price
- -
- -
- Market cap
- $52.7M
- $2.58B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2013
- News (4w)
- 7
- 12
- Recent ratings
- 0
- 23
XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Xencor Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., Janssen Biotech, Inc.; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Latest XBIT
- Amendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.
- Director Simard John bought $143,409 worth of shares (70,000 units at $2.05), increasing direct ownership by 2% to 4,261,690 units (SEC Form 4)
- SEC Form 10-Q filed by XBiotech Inc.
- SEC Form 4 filed by XBiotech Inc.
- SEC Form 3 filed by XBiotech Inc.
- Director Simard John bought $711,251 worth of shares (368,524 units at $1.93) (SEC Form 4)
- SEC Form 8-K filed by XBiotech Inc.
- XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
- XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
- SEC Form DEF 14A filed by XBiotech Inc.
Latest XNCR
- SEC Form SCHEDULE 13G filed by Xencor Inc.
- SR. VICE PRESIDENT & CFO Cornelissen Bart Jan sold $402,182 worth of shares (10,100 units at $39.82), decreasing direct ownership by 13% to 65,798 units (SEC Form 4)
- Director Ranieri Richard J exercised 75,755 shares at a strike of $18.85 and sold $3,189,435 worth of shares (81,252 units at $39.25), decreasing direct ownership by 23% to 18,514 units (SEC Form 4)
- SEC Form 144 filed by Xencor Inc.
- Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
- Amendment: SEC Form SCHEDULE 13G/A filed by Xencor Inc.
- SEC Form 10-Q filed by Xencor Inc.
- Xencor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Xencor Reports Third Quarter 2026 Financial Results
- Defining Moments in the Race for Biotech Breakthroughs